Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins FLT3 LOH||acute myeloid leukemia||sensitive||FLT3/CD3 Fabsc antibody + Quizartinib||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with the combination of Quizartinib (AC220) and an Fabsc FLT3/CD3 bi-specific antibody resulted in increased cytotoxicity over either agent alone in an acute myeloid leukemia cell line and patient-derived xenograft (PDX)-derived AML cells with a FLT3-ITD mutation and FLT3 loss of heterozygosity, leading to near complete eradication of AML cells in culture (PMID: 28895560).||28895560|
|FLT3 exon 14 ins FLT3 LOH||acute myeloid leukemia||sensitive||Quizartinib||Preclinical - Cell culture||Actionable||In a preclinical study, Quizartinib (AC220) inhibited proliferation of a acute myeloid leukemia cell line harboring a FLT3-ITD mutation with FLT3 loss of heterozygosity (PMID: 28895560).||28895560|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|